{"filings":[{"id":2310196,"accession_number":"0001178913-26-004178","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-08-18T12:00:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Entera Bio appoints Riccardo Paolo Camisasca as CMO ahead of EB613 Phase 3","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Riccardo Paolo Camisasca appointed Chief Medical Officer effective Aug 18, 2026.","He brings 30+ years experience; most recently Global Head of R&D at Sumitomo Pharma Switzerland.","Appointment strengthens clinical team ahead of planned EB613 Phase 3 initiation for osteoporosis.","Previously led R&D integration across Urovant, Enzyvant, Altavant, and Myovant at Sumitomo.","CEO Miranda Toledano cites his rare combination of developing drugs across global R&D organizations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2133039,"accession_number":"0001178913-26-003946","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-08-07T20:06:22+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio reports Q2 2026 results; FDA agrees to 12-month Phase 3 for EB613, $275M PIPE led by BVF","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted plan for single Phase 3 trial in ~750 postmenopausal women with osteoporosis, primary endpoint total hip BMD at Month 12; topline expected 2H 2028.","Oversubscribed $275M private placement led by BVF with participation from Longitude, Vivo, RA Capital, etc.; funds EB613 through NDA submission and extends cash runway into 2030.","Q2 2026 net loss $7.3M ($0.14/share) vs $2.7M ($0.06) in Q2 2025; R&D expenses $3.2M vs $1.5M.","Cash and equivalents $11.3M plus restricted cash $7.1M as of June 30, 2026; pro forma with $275M proceeds expected to fund operations into 2030.","EB612 IND filing planned 1H 2027 with OPKO; EB618 preclinical data presented at ENDO 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1913557,"accession_number":"0001178913-26-003617","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-07-28T20:12:49+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Entera Bio raises ~$275M in private placement for phase 3 osteoporosis trial; BVF gets board seats","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$275M via private placement of 122.96M shares and 11.84M pre-funded warrants at $2.04/share.","Proceeds to fund phase 3 registrational study of EB613 for postmenopausal osteoporosis and working capital.","BVF Partners (lead investor) gets right to designate two board directors, subject to ownership thresholds.","Two current independent directors (Haya Taitel and Yonatan Malca) to resign or not stand for reelection as part of succession plan.","Company to seek shareholder approval for equity plan increase and executive grants at special meeting in Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1691636,"accession_number":"0001178913-26-003510","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-07-16T20:07:03+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Entera Bio shareholders approve 2.5x increase in authorized shares to 350M and 2.5M share increase in equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized ordinary shares increased from 140,010,000 to 350,000,000 effective July 14, 2026.","2018 Equity Incentive Plan amended to add 2,500,000 ordinary shares for issuance.","All director nominees elected: Sean Ellis, Steven D. Rubin, Geno H. Germano (Class III, three-year terms).","Shareholders approved non-executive director compensation, share-based grants, and advisory say-on-pay.","Kesselman & Kesselman (PwC) ratified as independent auditor for FY 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94298,"accession_number":"0001178913-26-002455","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio Q1 net loss $3.5M; cash $20.4M; EB613 Phase 3 protocol submitted to FDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.5M ($0.07/share) vs $2.6M in Q1 2025; R&D expenses rose to $2.3M from $1.1M.","Cash $20.4M as of May 8, 2026, including BVF private placement proceeds; runway into Q1 2027.","EB613 Phase 3 protocol submitted to FDA; bridging study completed for single-tablet formulation.","EB612 hypoparathyroidism program prioritized with OPKO; IND expected late 2026.","Geno Germano appointed Chairman in February; Steve Rubin joined Board."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94297,"accession_number":"0001178913-26-002001","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Entera Bio raises $10M in private placement with BVF Partners to fund phase 3 osteoporosis study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$10.0M from sale of 7,827,789 units at $1.2775/unit to funds affiliated with BVF Partners LP.","Each unit consists of one ordinary share (or pre-funded warrant) and one warrant to purchase 1.5 ordinary shares at $1.24/share.","Warrants become exercisable 6 months after closing (April 2, 2026) and expire in 5 years; cash exercise could bring additional ~$14.5M.","Net proceeds intended to support initiation of phase 3 registrational study of EB613 for postmenopausal osteoporosis and for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106542,"accession_number":"0001178913-26-001792","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio FY2025 net loss $11.4M, cash runway to mid-Q3 2026; EB613 Phase 3 submitted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.4M ($0.25/sh) vs $9.5M in FY2024; R&D expenses $6.0M up from $4.5M.","Cash $14.9M at Dec 31, 2025 incl. $7.8M restricted for OPKO collab; operating cash burn $7.4M.","EB613 Phase 3 protocol submitted Mar 2026; FDA feedback expected late Apr 2026 with topline in H2 2028.","EB612 (LA-PTH) collaboration with OPKO expanded; IND filing expected late 2026.","EB618 (oral OXM) PK/PD validation complete; Phase 1 initiation dependent on injectable data by YE 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106541,"accession_number":"0001178913-26-000714","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Entera Bio submits streamlined Phase 3 protocol for EB613 to FDA; topline data H2 2028","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Phase 3 trial to enroll 750 postmenopausal women with osteoporosis; primary endpoint total hip BMD at 12 months.","Single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet candidate; no bridging needed.","FDA feedback expected within 60 days; topline results anticipated in second half of 2028, one year earlier than prior guidance.","12-month open-label extension study submitted; will run in parallel with potential NDA review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106540,"accession_number":"0001178913-26-000355","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Entera Bio appoints former Pfizer exec Geno J. Germano as Chairman, replacing Gerald Lieberman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Geno Germano appointed Class III director and Chairman of the Board effective February 4, 2026.","Gerald Lieberman resigned as Chairman and Director effective Feb 4, 2026, no disagreement.","Germano led Pfizer's $14B Global Innovative Pharma business as Group President until 2016.","Entera plans Phase 3 registrational study for EB613 (osteoporosis) and first-in-human for Long-Acting Oral PTH (hypoparathyroidism) in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106539,"accession_number":"0001178913-26-000300","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Entera Bio expands OPKO pact to include oral LA-PTH; appoints OPKO exec Rubin to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expanded collaboration covers once-daily oral LA-PTH tablet for hypoparathyroidism; 50/50 cost sharing.","IND filing for LA-PTH expected late 2026 after positive PK/PD data in December 2025.","Gerry Ostrov resigned as director effective Feb 1, 2026; Steven Rubin appointed as Class III director.","Rubin also chairs audit committee and serves on compensation committee; he is EVP at OPKO.","Oral OXM program progressing; Phase 1 injectable OXM data expected late 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122880,"accession_number":"0001178913-25-003851","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio reports Q3 net loss $3.2M; FDA agrees BMD endpoint for EB613 Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.2M ($0.07/share) vs $3.0M ($0.08/share) in Q3 2024; cash $16.6M through mid-Q3 2026.","FDA agreed BMD as primary endpoint for single Phase 3 trial of EB613 (oral PTH) for osteoporosis; supports NDA.","EB613 Phase 2 data showed significant BMD gains in younger postmenopausal women, presented at NAMS and ASBMR.","Next-gen EB613 Phase 1 trial on track for late 2025; GLP-2 and OXM programs with OPKO advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":42000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139580,"accession_number":"0001178913-25-002701","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio Q2 net loss $2.7M; FDA agrees on EB613 Phase 3 design with BMD endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA provided written concurrence on Phase 3 study for EB613, using total hip BMD as primary endpoint for NDA via 505(b)(2) pathway.","FDA waived dedicated oral carcinogenicity and DART studies for EB613, reducing regulatory burden.","Next-generation EB613 enters Phase 1 in November 2025; OPKO collaboration GLP-1/glucagon candidate OPK-88006 IND expected H1 2026.","Cash $18.9M including $8M restricted for OPKO; runway through mid-Q3 2026.","Q2 net loss $2.7M ($0.06 per share) vs $2.1M ($0.06 per share) a year ago; R&D up to $1.5M from $1.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":42000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139579,"accession_number":"0001178913-25-002484","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Entera Bio wins FDA agreement to use BMD as primary endpoint for EB613 Phase 3 osteoporosis study","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed single 24-month, placebo-controlled Phase 3 study with total hip BMD as primary endpoint; fracture incidence as key secondary.","Shift from traditional fracture-endpoint trials; no dedicated oral carcinogenicity or DART studies required by FDA.","Phase 3 study targets postmenopausal women; EB613 is first oral anabolic tablet for osteoporosis.","FDA's SABRE qualification still expected later this year but not needed to proceed.","CEO Miranda Toledano calls it a major milestone; no new osteoporosis drug approved by FDA since 2019."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139578,"accession_number":"0001178913-25-002406","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Entera Bio shareholders elect Haya Taitel to board; approve executive compensation amendments","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Haya Taitel elected as director for three-year term with 17,288,920 votes for, 3,069,140 against.","Revised compensation terms for CEO Miranda Toledano approved (19,524,783 for, 428,993 against).","Shareholders ratified Kesselman & Kesselman (PwC) as auditors for FY2025 with 26,617,578 votes for.","All seven proposals passed, including advisory say-on-pay and compensation policy amendments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157153,"accession_number":"0001178913-25-001673","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio Q1 net loss $2.6M ($0.06/sh); cash runway to mid-Q3 2026; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.6M ($0.06 per share) for Q1 2025 vs $2.0M ($0.05) in Q1 2024; operating expenses $2.6M.","Cash and equivalents $20.6M as of Mar 31, 2025; expects to fund operations through mid-Q3 2026.","EB613 (oral PTH) bone data presented at WCO-IOF-ESCEO Apr 2025; Next Gen EB613 Phase 1 planned H2 2025.","Collaboration with OPKO for oral GLP-1/Glucagon program; IND filing planned late 2025/early 2026.","Appointed Cherin Smith as EVP Clinical Ops (Mar) and Leslie Gautam as CBO (May 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":42000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175509,"accession_number":"0001178913-25-001110","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio reports FY2024 net loss of $9.5M; cash $21M as of March 28, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.5M ($0.25 per share) vs $8.9M ($0.31 per share) in FY2023.","Cash and equivalents $8.7M at Dec 31, 2024; $21M as of March 28, 2025 after new investments.","R&D expenses flat at $4.5M; G&A increased to $5.1M from $4.4M.","Entera and OPKO entered oral GLP-1/Glucagon license agreement; IND filing expected in 2025.","EB613 Phase 3 study planned pending FDA surrogate endpoint qualification; SABRE ruling awaited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175508,"accession_number":"0001178913-25-000857","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Entera Bio-OPKO collaboration: oral GLP-1/glucagon tablet, $8M equity investment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OPKO purchased 3,685,226 Entera shares at ~$2.17/share ($8M) to fund Entera's 40% development cost share through Phase 1.","Profit/cost split initially 60% OPKO / 40% Entera; opt-out after Phase 1 yields 85%/15% with OPKO funding.","Parties expect to file IND with FDA later in 2025 for oral tablet combining OPK-88006 and Entera's N-Tab™ technology.","OPKO subject to 12-month lockup on shares and 24-month standstill on acquiring additional Entera equity.","Preclinical data reported September 2024 showed favorable pharmacodynamic and pharmacokinetic profiles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175507,"accession_number":"0001178913-25-000080","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Entera Bio files legal opinion exhibit, no material business update","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing solely to submit Exhibit 5.1 (legal opinion of Herzog Fox & Neeman) and Exhibit 23.1 (consent).","No financial results, operational milestones, or guidance changes reported.","The warrant exercise price of $5.85 per ordinary share is unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192458,"accession_number":"0001178913-24-004020","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K/A","filed_at":"2024-12-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Entera Bio Board sets annual say-on-pay votes after shareholder vote","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders at July 31, 2024 annual meeting voted on frequency of advisory votes on executive compensation.","Frequency of one year received the highest number of votes cast.","Board determined to hold a non-binding advisory vote on executive compensation every year until further decision.","This 8-K/A amends the original 8-K filed August 2, 2024 to disclose the Board's frequency determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192459,"accession_number":"0001178913-24-003556","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio Q3 net loss $3.0M ($0.08/shr); cash $6.9M; awaits FDA SABRE ruling Jan 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.0M ($0.08 basic/diluted EPS) for Q3 2024 vs $2.4M ($0.08) in Q3 2023; operating expenses $3.0M vs $2.4M.","Cash and equivalents $6.9M; expects runway into Q3 2025.","EB613 (oral PTH) phase 3 prep ongoing; FDA decision on SABRE regulatory endpoint expected January 2025.","Oral GLP-1/glucagon (with OPKO) showed favorable PK/PD; plans to present at clinical conference.","Oral GLP-2 tablet for short bowel syndrome; final PK/PD data expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":99000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208929,"accession_number":"0001178913-24-002520","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio Q2 2024 net loss $2.1M; cash runway into Q3 2025; EB613 milestone expected","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.1M ($0.06 per share) vs $2.3M ($0.08) in Q2 2023; cash $9.1M at June 30, 2024.","R&D expenses $1.1M (down $0.1M YoY); G&A flat at $1.1M; operating expenses $2.2M.","EB613 (oral PTH) Phase 2 data published in JBMR; FDA SABRE endpoint ruling expected ~5 months.","EB612 hypoparathyroidism Phase 1 data at ENDO 2024; potential move to Phase 2 soon.","Collaboration with OPKO on oral GLP-2 (short bowel) and GLP-1/glucagon (obesity) ongoing; PK data due H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":57000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208928,"accession_number":"0001178913-24-002393","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Entera Bio shareholders approve all 8 proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Miranda Toledano and Yonatan Malca to three-year board terms with ~99% of votes cast.","Approved one-time CEO compensation grant for Miranda Toledano (14,365,894 for, 544,357 against).","Approved amendment to 2018 Equity Incentive Plan, increasing shares by 1,788,515 (14,131,640 for).","Ratified Kesselman & Kesselman (PwC) as independent auditors for FY2024 with overwhelming support.","Advisory vote on executive compensation passed; the most frequent frequency vote was 'one year'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226748,"accession_number":"0001178913-24-001681","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio Q1 net loss $2.0M; cash $9.2M; FDA catalyst path for EB613","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $2.0M ($0.05 per share) vs $2.2M ($0.08) in Q1 2023.","Cash $9.2M at March 31, 2024; runway into Q3 2025.","R&D expenses $0.7M (down from $0.9M); G&A flat at $1.3M.","FDA to rule on BMD as surrogate for fractures within 10 months – key catalyst for EB613 Phase 3.","Oral GLP-2 tablets showed 10-fold higher plasma exposure vs teduglutide; OXM PK data expected mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245713,"accession_number":"0001178913-24-000879","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio FY2023 net loss narrows to $8.9M; cash runway into Q2 2025; five oral peptide programs on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2023 was $8.9M ($0.31/share), down from $13.1M ($0.45/share) in FY2022.","Cash and cash equivalents $11.0M as of Dec 31, 2023; sufficient to fund operations through Q2 2025.","R&D expenses decreased to $4.5M from $5.8M; G&A decreased to $4.4M from $7.3M due to cost cuts.","Key 2024 milestones: Phase 1 PK data for EB612 (H1), pre-IND PK for GLP-2 (H1) and OXM (mid-2024), SABRE update.","Advancing five oral peptide programs: EB613 (osteoporosis), EB612 (hypoparathyroidism), GLP-2, OXM, stress fractures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245712,"accession_number":"0001178913-24-000794","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Entera Bio regains Nasdaq minimum bid price compliance, delisting risk removed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on March 1, 2024 confirming bid price compliance.","Ordinary shares closed at $1.00+ for 10 consecutive business days to satisfy rule.","Listing matter is now closed; no further action required.","Press release issued March 4, 2024 announcing the compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245711,"accession_number":"0001178913-24-000353","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Entera Bio files S-3 registration for resale of shares and warrants from December private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed registration statement on Form S-3 on Feb 2, 2024 per registration rights agreement from Dec 22, 2023 private placement.","Securities to be registered include ordinary shares and warrants (exercisable at $5.85 per share) issued to accredited investors.","Registration enables resale of private placement securities; does not constitute an offer to sell or solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245710,"accession_number":"0001178913-24-000035","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Entera Bio receives 180-day Nasdaq extension to June 24, 2024 to meet $1.00 bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted 180-day extension on Dec 27, 2023; new compliance deadline is June 24, 2024.","Must maintain closing bid price of at least $1.00 for 10 consecutive business days.","Company may pursue reverse stock split to regain compliance.","Failure to comply by June 24, 2024 could lead to delisting; trading continues for now.","Extended period has no immediate effect on listing or trading under symbol ENTX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263177,"accession_number":"0001178913-23-003962","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2023-12-26T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Entera Bio raises ~$6.6M in registered direct offering; issues shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate proceeds ~$6.6M from sale of 7,916,879 units at $0.835 each.","Each unit includes one ordinary share (or pre-funded warrant) and one five-year warrant to purchase an ordinary share at $1.00.","Warrants exercisable immediately; if all for cash, additional ~$7.9M potential proceeds.","CEO Miranda Toledano and Chairman Gerald Lieberman participated in the placement.","Company to file resale registration statement within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263176,"accession_number":"0001178913-23-003664","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio reports Q3 net loss $2.4M; advances oral peptide pipeline with OPKO collaboration, Phase 3-ready EB613","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.4M ($0.08/share) vs $3.1M ($0.11) in Q3 2022; cash $7.6M sufficient into Q3 2024.","FDA concurred that 2-year Phase 3 study with BMD endpoint could support NDA for EB613 (oral PTH) in osteoporosis.","Collaboration with OPKO to develop oral GLP-2 for short bowel syndrome and oxyntomodulin for obesity; updates expected H1 2024.","EB612 (oral PTH for hypoparathyroidism) Phase 2a met endpoints; ongoing PK/PD study results expected end of 2023.","Operating expenses $2.4M, down from $2.9M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280377,"accession_number":"0001178913-23-003142","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Entera Bio shareholders approve all proposals at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Lieberman, Ostrov, and Ellis elected with over 11.2M votes for each.","Compensation items for CEO Toledano and Director Taitel ratified by large majorities.","Board authorized to effect reverse share split (5:1 to 11:1) by Sept 2024 if needed.","Kesselman & Kesselman (PwC) ratified as independent auditor for FY 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280376,"accession_number":"0001178913-23-002832","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio reports H1 net loss $4.5M, cash $9.1M; updates on EB613 and EB612 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["H1 2023 net loss $4.5M ($0.16/share) vs $7.0M ($0.24) in H1 2022.","Cash and equivalents $9.1M expected to fund operations into Q3 2024.","R&D expenses $2.1M (down 32% YoY); G&A $2.4M (down 41% YoY).","EB613 Phase 3 initiation depends on FDA review of FNIH-ASBMR SABRE BQP qualification.","Phase 1B study of next-gen EB612 platform (45 subjects, 3 cohorts) started May 2023; H2 2023 data readout expected."],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298922,"accession_number":"0001178913-23-002344","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Entera Bio receives Nasdaq minimum bid price deficiency notice; faces potential delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice for failing $1.00 minimum bid price for 30 consecutive business days.","Initial 180-day compliance period ends December 26, 2023; must close at $1.00 for 10 consecutive days.","If not cured, may qualify for additional 180-day period with conditions including reverse stock split.","Company states the notice has no effect on its business operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298921,"accession_number":"0001178913-23-002305","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Entera Bio warrants to expire July 2, 2023; trading suspended June 28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrants (ENTXW) expire at 5:00 p.m. ET on July 2, 2023 per their terms.","Trading of warrants suspended after close of business on June 28, 2023.","Nasdaq to file Form 25 to delist and deregister the warrants under Section 12(b).","Ordinary shares (ENTX) listing unaffected by the warrant expiration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298920,"accession_number":"0001178913-23-002176","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Entera Bio appoints Haya Taitel to Board of Directors, Class II","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded Class II from one to two directors; Taitel appointed June 4, 2023, term through 2025 annual meeting.","Taitel is Head of Sanofi's Global Transplant Franchise; previously Kadmon CCO (Rezurock launch) and Johnson & Johnson leader.","Board determined Taitel independent under SEC and Nasdaq rules; no material transactions with company.","Taitel to receive standard non-employee director compensation (cash retainers + annual option grants under 2018 plan)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298919,"accession_number":"0001178913-23-001714","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio Q1 net loss $2.2M vs $3.8M YoY; cash $10.7M into Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.2M, $0.08 per share, compared to $3.8M, $0.13 per share in Q1 2022.","Cash and equivalents $10.7M as of Mar 31, 2023; expects cash to fund ops into Q3 2024.","R&D expenses $0.9M (down 47% YoY); G&A expenses $1.3M (down 41% YoY).","Plans to initiate PK study of oral PTH(1-34) for hypoparathyroidism H1 2023, topline H2 2023.","Amgen research collaboration discontinued by mutual agreement after 4+ years."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319101,"accession_number":"0001178913-23-001271","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio posts 2022 net loss of $13.1M; cash runway into Q3 2024; FDA accepts Type D meeting for EB613","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.1M ($0.45/share) vs $12.2M ($0.47/share) in 2021; revenues $134K, down from $571K.","Cash and equivalents $12.3M; expects runway into Q3 2024, excluding Phase 3 EB613 funding.","FDA accepted Type D meeting to confirm placebo-controlled Phase 3 design with TH BMD endpoint for EB613.","EB613 (oral teriparatide) positioned as first daily tablet anabolic therapy for osteoporosis; Phase 2 results positive.","New formulation EB612 (PTH(1-34) for hypoparathyroidism) entering Phase 1 PK study, targeting Phase 2 in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337324,"accession_number":"0001178913-22-004137","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2022-11-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Entera Bio receives Nasdaq delinquency notice for minimum bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Entera Bio on Nov 21, 2022 that ordinary shares fail minimum $1.00 bid price for 30 consecutive business days.","Company has 180 calendar days, until May 22, 2023, to regain compliance with minimum bid price requirement.","To cure, closing bid must be at least $1.00 for a minimum of 10 consecutive business days before deadline.","If non-compliant by May 22, 2023, Entera may seek an additional 180-day period subject to meeting other listing standards.","Notice has no immediate effect on the company's business operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337323,"accession_number":"0001178913-22-003937","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio announces FDA agreement for single pivotal Phase 3 study of oral PTH tablet EB613 with BMD endpoint","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed that a single placebo-controlled Phase 3 study with total hip BMD as primary endpoint can support NDA for EB613.","EB613 is the first daily oral tablet formulation of teriparatide (Forteo), targeting post-menopausal osteoporosis.","Patient enrollment in the pivotal Phase 3 study is expected to commence in 2023.","Q3 2022 net loss $3.1M ($0.11 per share); cash $14.3M, expected to fund operations through Q2 2023.","Revenue was $8K (down from $140K) primarily due to finalization of Amgen pre-clinical services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337322,"accession_number":"0001178913-22-003589","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Entera Bio receives FDA agreement that single Phase 3 study could support NDA for EB613","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed single Phase 3 placebo-controlled trial could support NDA for oral teriparatide EB613 via 505(b)(2) pathway.","Primary endpoint: change in Total Hip BMD at 24 months in post-menopausal osteoporosis patients.","Planned 400 EB613 patients with 2:1 randomization; eligible patients BMD T-score ≤-2.5 to 3.0, no major fracture history.","Company to submit relative PK data comparing oral EB613 to subcutaneous Forteo.","Expects to initiate Phase 3 enrollment in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354695,"accession_number":"0001178913-22-003369","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2022-09-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Entera Bio shareholders elect Yonatan Malca and approve all proposals at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Yonatan Malca elected to board for three-year term; 11,060,520 votes for, 47,457 against.","CEO Miranda Toledano's compensation ratified: 8,074,581 for, 2,959,002 against.","Amendment to 2018 equity plan increasing shares by 576,188 approved: 8,420,408 for.","Kesselman & Kesselman (PwC) ratified as auditor for FY2022 with 11,061,302 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354694,"accession_number":"0001178913-22-003312","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2022-09-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Entera Bio enters into $5M ATM equity facility with SVB; terminates prior B. Riley ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with SVB Securities for at-the-market offering of up to 5,000,000 ordinary shares.","Agent commission set at 3.0% of gross sales price per ordinary share sold.","Prior B. Riley Securities ATM terminated effective Aug 30, 2022; no shares were sold under it.","Net proceeds planned for general corporate purposes including R&D, clinical trials, and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354693,"accession_number":"0001178913-22-003055","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio reports Q2 results: submits EB613 protocol to FDA, net loss $7.0M, cash $17.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Submitted proposed registrational protocol for EB613 (oral PTH) to FDA; expects Type C meeting in H2 2022.","Finalizing optimized formulation for EB612 (hypoparathyroidism); first-in-human PK study planned H1 2023.","Net loss $7.0M ($0.24 per share) for six months ended June 30, 2022, vs $4.9M ($0.21) in prior year period.","Revenue $112k, down from $226k; operating expenses $7.1M, up from $5.0M.","Cash $17.3M as of June 30, 2022, expected to fund operations through Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":112000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354692,"accession_number":"0001178913-22-002842","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Entera Bio releases updated corporate presentation; no specific new financial data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation made available on August 1, 2022, on company website.","Exhibit 99.1 included but text truncated; no financial metrics or guidance changes extracted.","Presentation likely covers pipeline and business overview; no material events announced.","Stock tickers: ENTX (ordinary shares) and ENTXW (warrants)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354691,"accession_number":"0001178913-22-002674","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2022-07-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Entera Bio appoints Miranda Toledano CEO, Dana Yaacov-Garbeli CFO; former CEO Jamas departs with $411K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Miranda Toledano as CEO effective July 15, 2022; she had served as CBO/CFO and director since 2018.","Toledano's amended employment: annual employer cost $380K, bonus eligibility 60% of base salary, option grant of 600K shares at $1.40.","Additional performance milestone options for 200K shares under long-term incentive.","Dana Yaacov-Garbeli promoted to CFO effective July 15; she was Israel-based CFO since June 2019.","Former CEO Spiros Jamas receives lump sum $411,666.67 (13 months salary) and extension of vested option exercise period for 492,832 shares for two years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372700,"accession_number":"0001178913-22-002398","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Entera Bio President of R&D & Director resigns under separation deal with cash and option benefits","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Phillip Schwartz resigns as President of R&D (effective July 21, 2022) and from Board (immediate); no disagreement.","Cash separation payment of ~$155,900 plus ~$213,952 in accrued benefits; also fully accelerated 100,000 option shares subject to shareholder approval.","Proposed consulting agreement for business development services with 14-day termination notice.","Schwartz agrees to non-disparagement, mutual release, and voting/standstill restrictions until after 2023 AGM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372699,"accession_number":"0001178913-22-002217","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Entera Bio amends ATM sales agreement with B. Riley Securities to reflect loss of foreign private issuer status","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Entered into Amended and Restated At Market Issuance Sales Agreement with B. Riley Securities dated May 27, 2022.","Amendment made to reflect that Entera Bio is no longer a foreign private issuer.","All material terms of the original agreement remain unchanged.","Agreement allows for at-the-market offerings of ordinary shares under a Form S-3 registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372698,"accession_number":"0001178913-22-001980","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Entera Bio appoints Miranda Toledano as CFO, CBO, and Head of Corp Strategy; prior CFO Ratan departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Miranda Toledano appointed Chief Business Officer, CFO, and Head of Corporate Strategy effective May 16, 2022.","Toledano loses independence; no longer serves on Compensation or Audit Committees; vacancies to be filled.","Annual employer cost of $350,000; options for 500k shares at $2.02, vesting over 4 years (25% at year 1).","Prior CFO Ramesh Ratan no longer with company; Dana Yaacov-Garbeli remains as principal accounting officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372697,"accession_number":"0001178913-22-001915","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio Q1 net loss $3.8M ($0.13/shr); cash $20.1M, expects funding into Q4 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $68K from Amgen R&D services, down from $157K YoY; operating expenses $3.8M vs $2.4M.","Cash $20.1M at March 31, 2022 (vs $24.9M Dec 31); expects to fund operations into Q4 2022.","EB613 (oral PTH for osteoporosis): FDA completed CMC review; Phase 3 trial design underway.","Market study: >15M U.S. osteoporosis patients, 75% untreated; clinicians favor oral anabolic.","EB612 hypoparathyroidism: orphan drug status; working on improved formulation for next trial."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":68000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391521,"accession_number":"0001178913-22-000990","cik":1638097,"company_name":"Entera Bio Ltd.","ticker":"ENTXW","form_type":"8-K","filed_at":"2022-03-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Entera Bio reports $12.2M net loss for 2021; guides FY2022 operating loss of $25-30M; EB613 Phase 3 trial in 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $571k in 2021 vs $365k in 2020; net loss $12.2M ($0.47 per share) vs $11.2M ($0.67 per share).","Cash $24.9M at Dec 31, 2021; $21.7M at Mar 1, 2022; expects FY2022 operating loss $25-30M.","EB613 (osteoporosis) Phase 3 pivotal trial expected to start in 2022 after positive FDA End of Phase 2 meeting.","EB612 (hypoparathyroidism) improved formulation; next clinical trial planned in 2022; Orphan Drug status FDA and EMA.","Engaged Torreya Capital as financial advisor for non-dilutive strategic alliances for EB613."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}